Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Speculators remain skeptical of Veeco Instruments (VECO)

Since March 2009, Veeco Instruments Inc. ’s ( NASDAQ: VECO , Stock Forum ) steep ascent has been underlined by its 10-week and 20-week moving averages. These intermediate-term trendlines have contained all of VECO's weekly closes in the intervening months, ...

Bob Moriarty | It’s Time to Buy Silver!

In this interview, Bob Moriarty of 321gold sits down with Maurice Jackson of Proven and Probable to discuss a number of important topics ranging from hospital cost incentives regarding the COVID-19, and the how the economy...

Reigniting the Cannabis Oral Delivery System Marketplace

This podcast is part of our Cannabis Sector CEO interview series, and our mission going forward is to help listeners and investors understand more about investment opportunities in the public marketplace. Stockhouse Media's Dave Jackson was recently joined live with Bra...

Power of Narratives and Gold

The U.S. manufacturing sector has been growing weaker recently, entering recession. How serious is this contraction, and does it have the power to spill over to the broader economy? Let’s turn to gold – how far can these developments take us on the yellow brick...

Neurotrope's Shares Double on Phase 2 Alzheimer's Study Data and $2.7 Million NIH Grant

Neurotrope's shares traded higher today after reporting results from its Phase 2 "203" clinical trial of Byrostatin-1 for treatment of moderately severe to severe Alzheimer's patients. The firm has also been awarded a $2.7 million grant from the National Institutes of Health t...

Living in a virus-controlled world

As the coronavirus pandemic continues to infect populations, though in some countries it is slowing, talk has shifted to re-opening economies, and to manufacturing a vaccine that drug companies hope will not only work, but can be distributed at large enough doses to provide ...

Nov 17th 2019, Crypto Chartbook – Indicator divergence

Indicator divergence With a vast following of market speculators, we receive a consistent inflow of questions and comments about the market. Traders ask in our our telegram channel, in which we post our trades live, and via e mail as well as in our public appearances, ab...

Buzz on the Bullboards: Who’s Who in the Business of COVID

(Stock photo.) It’s another week of the COVID-19 pandemic, which means another week where we see the healthcare sector continue to dominate investor attention … and for good reason. Small-cap investors are always on the lookout for the most curre...

Titans in Mining: An Interview with Rick Rule, Part 2

After the first part of my interview with Rick Rule generated quite a bit of attention, I'm pleased to continue with the interview in this second, and equally extensive, part, in a series of no less than four parts. As Rick is one of the best speakers in the mining sect...

BASF and Cardiol Therapeutics recommended buys; TUI rides momentum

BASF (OTCQX:BASFY) shares have gained over 30% within six months. But is the rally in BASF shares slowly running out of steam? The fact that the stock did not rise sharply yesterday despite a significant price target increase suggests this is the case. Many experts see ...
1 2 3 4 5 6 7 8 9 10 ...